AstraZeneca Shares Plunge 9% as Heart Drug Wainua Fails Late-Stage Trial

According to its statement, AstraZeneca's Wainua, a drug being tested for rare heart disease patients, failed to meet its primary endpoint compared to placebo in reducing patient mortality and recurrent cardiac events within 140 weeks. The announcement triggered a stock decline of 9%, marking the company's worst trading day in over six years.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments